https://www.medpagetoday.com/special-reports/exclusives/93658?xid=nl_mpt_DHE_2021-07-21&eun=g1787146d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-07-21&utm_term=NL_Daily_DHE_dual-gmail-definition
Preprint publisher finds evidence of plagiarism, problems with raw data A large Egyptian study of ivermectin for COVID-19 patients has been retracted over concerns of plagiarism and serious problems with their raw data, the publisher confirmed to *MedPage Today*. Michele Avissar-Whiting, PhD, editor-in-chief of the preprint server *Research Square*, said in an emailed statement that the study was withdrawn <https://www.researchsquare.com/article/rs-100956/v4> on July 14 "because we were presented with evidence of both plagiarism and anomalies in the dataset associated with the study, neither of which could reasonably be addressed by the author issuing a revised version of the paper." Hill added that his team will also include a recently published 500-patient randomized controlled trial from Argentina, published in *BMC Infectious Diseases* <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06348-5>, which found no effect for ivermectin in terms of preventing hospitalization in patients with COVID-19. It also found that those who received ivermectin required invasive ventilation sooner than those on placebo.
